Abstract
No public abstract is available from the verified source records.
Jonathan Heywood, Helen Farnham, Elizabeth Jackson, Katie Steimel, Sarah Brown, Alexander Riordan
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Standardizing Research Methods for Opioid Dose Comparison: The NIH HEAL Morphine Milligram Equivalent Calculator
10.1097/j.pain.0000000000003529 · 2025
From Kratom to 7-Hydroxymitragynine: Evolution of a Natural Remedy into a Public-Health Threat
10.1080/13880209.2025.2590311 · 2025
Unresolved referenced work
Kept as external metadata until matched
Quantitative analysis of 7-hydroxymitragynine in commercial kratom products and its stability under chemical and physiological conditions
10.1016/j.phytochem.2026.114871 · 2026
The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study
10.1124/dmd.121.000640 · 2022
A Detailed Exploration Into the Association of Prescribed Opioid Dosage and Overdose Deaths Among Patients With Chronic Pain
10.1097/mlr.0000000000000505 · 2016
Case Report: Cannabis and Kratom-Induced Self-Amputation of Ears and Penis
10.3389/fpsyt.2025.1479863 · 2025
datacite
Confidence 0%
Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom
10.1093/jaoacint/qsaf094 · 2026
A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom
10.1016/j.jep.2017.03.020 · 2017
Oxidative Metabolism as a Modulator of Kratom’s Biological Actions
10.1021/acs.jmedchem.1c01111 · 2021
Exploring the Chemistry of Alkaloids from Malaysian Mitragyna speciosa (Kratom) and the Role of Oxindoles on Human Opioid Receptors
10.1021/acs.jnatprod.0c01055 · 2021
Inches, Centimeters, and Yards: Overlooked Definition Choices Inhibit Interpretation of Morphine Equivalence
10.1097/ajp.0000000000000948 · 2021
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
10.15585/mmwr.rr6501e1 · 2016
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
10.15585/mmwr.rr7103a1 · 2022
10.1016/b978-0-443-27412-1.00007-9
10.1016/b978-0-443-27412-1.00007-9
The Role of Opioid Prescription in Incident Opioid Abuse and Dependence Among Individuals With Chronic Non-Cancer Pain: The Role of Opioid Prescription
10.1097/ajp.0000000000000021 · 2014
Kratom (Mitragyna speciosa Korth) for a New Medicinal: a Review of Pharmacological and Compound Analysis
2021
Analysis of heavy metals content in commercially available kratom products in Richmond, Virginia
10.1016/j.forc.2023.100474 · 2023
A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products
10.1016/j.forsciint.2019.04.009 · 2019
Unresolved referenced work
Kept as external metadata until matched
Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic
10.1016/j.drugalcdep.2020.107849 · 2020
From Kratom to Semi-Synthetic Opioids: The Rise and Risks of MGM-15
10.1002/dta.3952 · 2025
Prevalence and Use Patterns of Kratom (Mitragyna speciosa Korth.) in a US Nationally Representative Sample
2025
The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal
10.1111/adb.70126 · 2026
Kratom safety and toxicology in the public health context: research needs to better inform regulation
10.3389/fphar.2024.1403140 · 2024
Beneficial and Adverse Health Effects of Kratom (Mitragyna speciosa): A Critical Review of the Literature
10.1016/j.fct.2024.114913 · 2024
De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing
10.1016/j.drugalcdep.2025.112701 · 2025
The respiratory depressant effects of mitragynine are limited by its conversion to 7-OH mitragynine
10.1111/bph.15832 · 2022
The Effects of Mitragynine and Morphine on Schedule-Controlled Responding and Antinociception in Rats
10.1007/s00213-019-05247-7 · 2019
Indole Alkaloids of a Thai Medicinal Herb, Mitragyna speciosa, That Has Opioid Agonistic Effect in Guinea-Pig Ileum
10.1055/s-2005-837822 · 2005
Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder
2024
Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy
10.1021/acsptsci.0c00075 · 2020
Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats
10.1124/jpet.122.001525 · 2023
Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)
10.1080/00498254.2018.1552819 · 2019
Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant “kratom” (Mitragyna speciosa) by LC-ESI-MS
10.1007/s11419-009-0070-5 · 2009
Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
10.1021/jacs.6b00360 · 2016
Mitragynine and 7-Hydroxymitragynine: Bidirectional Effects on Breathing in Rats
10.1016/j.jpet.2025.103720 · doi-reference
Opioid Receptor Agonistic Characteristics of Mitragynine Pseudoindoxyl in Comparison With Mitragynine Derived From Thai Medicinal Plant Mitragyna speciosa
10.1016/s0306-3623(98)00265-1 · doi-reference
Inhibitory Effect of Mitragynine, an Alkaloid With Analgesic Effect From Thai Medicinal Plant Mitragyna speciosa, on Electrically Stimulated Contraction of Isolated Guinea-Pig Ileum Through the Opioid Receptor
10.1016/s0024-3205(97)00023-4 · doi-reference
Mitragynine pseudoindoxyl withdrawal treated with macro-dosed buprenorphine induction: A case report and review of the literature
10.3390/psychoactives5010007 · doi-reference
Fatal Mitragynine-Associated Toxicity in Canada: A Case Report and Review of the Literature
10.1177/1925362118782076 · doi-reference
De Facto Long-term Opioid Therapy for Non-Cancer Pain
10.1097/ajp.0b013e318169d03b · doi-reference
Uniform assessment and ranking of Mu receptor binding constants for selected opioid drugs
10.1016/j.yrtph.2010.12.007 · doi-reference
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2
10.1021/acs.jmedchem.6b00748 · doi-reference
Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025
10.15585/mmwr.mm7511a1 · doi-reference
Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions
10.1038/s41598-020-76119-w · doi-reference
Studies on the Synthesis and Opioid Agonistic Activities of Mitragynine-Related Indole Alkaloids: Discovery of Opioid Agonists Structurally Different From Other Opioid Ligands
10.1021/jm010576e · doi-reference
Lateral Flow Assessment and Unanticipated Toxicity of Kratom
10.1021/acs.chemrestox.8b00218 · doi-reference
Ecological Momentary Assessment of Self-Reported Kratom Use, Effects, and Motivations Among US Adults
10.1001/jamanetworkopen.2023.53401 · doi-reference
The Acute Adverse Health Effects of Kratom: An Evaluation of Case Reports
10.3389/fphar.2025.1620601 · doi-reference
Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users
10.1016/j.drugalcdep.2014.03.017 · doi-reference
Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia
10.1016/j.jep.2017.12.017 · doi-reference
Avoiding False Identification of 7-Hydroxymitragynine in Kratom Products Using a Multicriteria LC-MS Confirmation
10.1021/jasms.6c00088 · doi-reference
Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography–tandem mass spectrometry
10.1002/dta.2604 · doi-reference
Seasonal and Geographic Variation in Alkaloid Content of Kratom (Mitragyna speciosa (Korth.) Havil.) from Thailand
10.3390/plants12040949 · doi-reference
Clarifying intrinsic efficacy, partial agonism, and full agonism: the case of buprenorphine
10.1016/j.bja.2023.10.041 · doi-reference
Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats
10.1016/j.jep.2013.02.008 · doi-reference
Kratom Addiction per DSM-5 SUD Criteria, and Kratom Physical Dependence: Insights From Dosing Amount Versus Frequency
10.1016/j.drugalcdep.2024.111329 · doi-reference
Substance Use Disorder Following Consumption of a Novel Synthetic 7-Hydroxymitragynine Product
10.1097/adm.0000000000001603 · doi-reference
Cardio-Pulmonary Arrest in a Patient Revived With Naloxone Following Reported Use of 7-Hydroxymitragynine
10.1080/15563650.2025.2565428 · doi-reference
Evaluation of the Mitragynine Content, Levels of Toxic Metals and the Presence of Microbes in Kratom Products Purchased in the Western Suburbs of Chicago
10.3390/ijerph17155512 · doi-reference
An Exploratory Study of the Safety Profile and Neurocognitive Function After Single Doses of Mitragynine in Humans
10.1007/s00213-024-06734-2 · doi-reference
Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review
10.1007/s40429-023-00478-3 · doi-reference
A New Indole Alkaloid, 7 alpha-Hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand
10.1055/s-2006-959578 · doi-reference
An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine
10.3390/ph16101397 · doi-reference
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats
10.1124/jpet.120.000189 · doi-reference
The Mitragyna speciosa (Kratom) Alkaloid Mitragynine: Analysis of Adrenergic α2 Receptor Activity In Vitro and In Vivo
10.1016/j.ejphar.2024.176863 · doi-reference
A Synthesis of Oral Morphine Equivalents (OME) for Opioid Utilisation Studies
10.1002/pds.3945 · doi-reference
Prevalence and Correlates of Past-year Kratom Use Among US Adults: Findings From the 2021-2023 National Survey on Drug Use and Health
10.1097/adm.0000000000001637 · doi-reference
Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers
10.1021/acsptsci.3c00335 · doi-reference
An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations
10.1080/17512433.2024.2305798 · doi-reference
Orally Active Opioid m/d Dual Agonist MGM-16, a Derivative of the Indole Alkaloid Mitragynine, Exhibits Potent Antiallodynic Effect on Neuropathic Pain in Mices
10.1124/jpet.113.208108 · doi-reference
Antinociceptive Effect of 7-Hydroxymitragynine in Mice: Discovery of an Orally Active Opioid Analgesic From the Thai Medicinal Herb Mitragyna speciosa
10.1016/j.lfs.2003.09.054 · doi-reference
Involvement of Mu-Opioid Receptors in Antinociception and Inhibition of Gastrointestinal Transit Induced by 7-Hydroxymitragynine, Isolated From Thai Herbal Medicine Mitragyna speciosa
10.1016/j.ejphar.2006.08.013 · doi-reference
Postmortem Mitragynine Distribution in a Single Drug Fatality Case
10.1177/19253621231160417 · doi-reference
Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: A case report
10.1016/j.japh.2026.103047 · doi-reference